Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Obstetrics and gynaecology indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Abnormal cervical results and colposcopy

Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate haemorrhage, infection or suspected invasion

Severe bleeding after cervical excision, fever with pelvic pain or offensive discharge, haemodynamic compromise, or a colposcopic appearance suspicious for invasive cancer requires urgent assessment outside routine recall.

Action: Check observations and bleeding, obtain senior gynaecology review, resuscitate and treat infection when indicated, and expedite diagnostic biopsy and cancer-MDT involvement when invasion is possible.

Purpose and principles

Translate HPV and cytology combinations into the correct surveillance, colposcopy, biopsy, treatment and test-of-cure pathway while minimising avoidable excision.

An abnormal screening result describes risk, not a cancer diagnosis. The report combines hrHPV status with cytological triage and previous results. Explain that HPV is common, may persist silently for years and cannot date transmission. Then give a concrete plan: whether the next event is a repeat sample, colposcopy, biopsy, excision or test of cure, who will arrange it and what symptoms should bypass that plan.

The routine HPV-persistence pathway starts with hrHPV-positive, cytology-negative screening. Repeat at 12 months. If HPV has cleared, return to the programme-calculated routine recall. If HPV remains positive and cytology remains negative, repeat after a further 12 months. At the 24-month test, continued hrHPV positivity leads to colposcopy regardless of cytology because this is the third consecutive positive result. Any abnormal cytology at the initial or repeat stage prompts colposcopy sooner.

Technical failure has a different clock. When hrHPV is unavailable or cytology is inadequate, the sample is repeated in no less than 3 months, allowing cervical epithelium to recover and improving adequacy. The programme permits up to two consecutive unavailable or inadequate results and refers at the second. Repeating immediately or indefinitely in primary care can cause another poor sample and delay visual assessment.

Indications, selection and cautions

HPV persistence without cytological change

Sequential hrHPV-positive, cytology-negative results are managed by the 12-month and 24-month pathway, with colposcopy after the third consecutive positive result.

Cytology-positive referral

Borderline or worse reflex cytology in an hrHPV-positive cervical sample moves directly to colposcopy rather than waiting to demonstrate another year of persistence.

Low-grade histology

CIN1 represents low-grade squamous intraepithelial disease and usually enters surveillance because spontaneous regression is common and excision has reproductive harms.

High-grade histology

CIN3 requires treatment after invasion is excluded; CIN2 needs a documented choice between treatment and appropriately selected specialist surveillance.

Glandular abnormality

CGIN or SMILE may occupy the endocervical canal and requires excisional histological assessment plus a longer, two-sample test-of-cure protocol.

Red flags requiring action

  • A visible irregular, necrotic, ulcerated or contact-bleeding cervical mass must be managed as suspected invasive cancer rather than as a screening-grade abnormality.
  • Heavy bleeding that soaks pads rapidly, clots, dizziness, syncope, tachycardia or hypotension after LLETZ requires same-day emergency assessment.
  • Fever, escalating pelvic pain, offensive discharge or systemic illness after biopsy or excision suggests infection and needs prompt clinical review.

Method and interpretation

  1. 01
    Repeat hrHPV with reflex cytologyFirst step
    Why
    Determine whether an initially cytology-negative high-risk HPV infection clears, persists or develops cellular abnormality.
    Interpretation and limitations
    Clearance at 12 or 24 months returns to recall; continued positivity at 24 months or abnormal cytology at any repeat requires colposcopy.
  2. 02
    Colposcopic examination
    Why
    Assess the transformation zone, locate abnormal epithelium, judge examination adequacy and select biopsy sites.
    Interpretation and limitations
    A normal view reduces risk only when the examination is adequate and matches the referral result; discordant high-grade cytology requires MDT review or diagnostic excision.
  3. 03
    Directed punch biopsy
    Why
    Obtain tissue from a colposcopically abnormal area for grading and exclusion of stromal invasion.
    Interpretation and limitations
    Histology guides surveillance or treatment, but a superficial or poorly targeted negative specimen cannot resolve a suspicious mass or inaccessible endocervical lesion.
  4. 04
    Excisional specimen by LLETZ or cone
    Why
    Treat high-grade disease while assessing depth, margins, glandular involvement and unsuspected invasion.
    Interpretation and limitations
    Interpret margins and pathology with the pretreatment cytology and colposcopy; fragmented or thermally damaged tissue can limit staging and may require further assessment.

Clinical next steps

01Screening triageMatch result combination to timingFirst stepAn hrHPV-positive or technically inadequate screening report is issued.+
  1. 1Read HPV, reflex cytology and prior results together, then tell the person clearly that the report estimates precancer risk rather than confirming cancer.
  2. 2Refer hrHPV-positive abnormal cytology to colposcopy; repeat hrHPV-positive negative cytology at 12 months and again at 24 months if still positive and cytology negative.
  3. 3Refer persistent hrHPV positivity at 24 months regardless of cytology, and repeat unavailable or inadequate testing after at least 3 months with referral after the second consecutive failure.
02ColposcopyProve grade before proportionate treatmentThe programme has referred abnormal cytology, persistent HPV, repeated inadequacy or a complex discordant result.+
  1. 1Document pregnancy, symptoms, previous treatment and reproductive priorities, then examine the complete transformation zone and record whether the assessment is adequate.

Risks, monitoring and follow-up

  • Track every colposcopy referral to attendance, biopsy result, MDT decision, treatment and final recall code; an appointment letter alone is not pathway completion.
  • Record lesion grade, transformation-zone visibility, excision dimensions and histological margins so later obstetric and recurrence-risk decisions have context.
  • After conservative CIN2 management, maintain the specialist interval and escalate persistence, progression, poor visibility or unreliable attendance rather than extending observation silently.
  • Confirm the 6-month test of cure and the distinct 18-month CGIN test, using direct colposcopy referral for any hrHPV-positive follow-up result.
  • Ask after treatment about bleeding, discharge, pain, future pregnancy and psychological impact, and provide a direct contact route for unexpected deterioration.

Special situations

Persistence is chronological evidence

A third positive HPV result at the 24-month point raises risk even when every reflex cytology report remains negative, which is why colposcopy follows.

Adequacy changes reassurance

A normal colposcopic impression is most meaningful only when the transformation zone and lesion limits are fully visualised and the result explains the referral abnormality.

Excision has two purposes

LLETZ can remove precancer and also reveal margins or occult invasion, making specimen integrity and orientation clinically important rather than administrative details.

TOC remains three-year first

The routine five-year interval does not immediately follow a negative six-month CIN test of cure; the next screen remains due at three years.

Pregnancy protects timing not cancer

CIN treatment is usually deferred in pregnancy, but an appearance concerning for invasion must still be biopsied and managed urgently by experts.

Common pitfalls

  1. 01

    Sending every isolated hrHPV-positive, cytology-negative result straight to treatment rather than using the persistence pathway.

  2. 02

    Repeating an inadequate cervical sample immediately instead of waiting at least three months or referring after repeated failure.

  3. 03

    Treating persistent HPV when colposcopy shows no disease, exposing the cervix to harm without a histological target.

  4. 04

    Reassuring from a negative punch biopsy when high-grade cytology, an inadequate examination or a suspicious mass remains unexplained.

  5. 05

    Applying the CIN test-of-cure schedule to completely excised CGIN and omitting its second test at 18 months.

  6. 06

    Ignoring excision depth and repeat treatment when counselling about future preterm birth and cervical stenosis.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA

Escalating persistent HPV

A routine cervical sample is hrHPV positive with negative cytology. The same combination remains at 12 months and again at 24 months. What should the programme arrange now?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Obstetrics and gynaecology topics →
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS cervical screening care pathway
  • NHS colposcopy management guidance
  • NHS colposcopic diagnosis and follow-up
  • NHS sample-taker result guidance
  • NHS pregnancy and hysterectomy colposcopy guidance

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftAwaiting review

Colposcopy uses magnified inspection of the cervix and transformation zone, usually after dilute acetic acid. Record whether the squamocolumnar junction and lesion upper limit are fully visible, lesion site and size, colposcopic impression, biopsies and correlation with referral cytology. A directed punch biopsy supplies histology when the grade is uncertain. High-grade cytology with an inadequate examination may require diagnostic excision because a negative ectocervical biopsy cannot exclude an endocervical lesion.

Histology distinguishes CIN from invasion. CIN1 is low-grade HPV-associated change with substantial regression potential; surveillance is usually safer than immediate excision. CIN3 has a higher progression risk and is treated. CIN2 lies between them: observation can be considered for carefully selected people when the transformation zone is fully assessable, invasion and glandular disease are excluded, and reliable colposcopic follow-up is possible. The decision accounts for age, reproductive priorities, lesion persistence and ability to attend, not preference alone.

LLETZ removes the transformation zone and provides a specimen for margins and occult invasion. Explain immediate pain and bleeding, delayed haemorrhage, infection and cervical stenosis. Future preterm birth risk rises with increasing depth and repeated excision, so treatment should remove enough tissue for oncological safety without routine excessive depth. Ablative treatment lacks a specimen and is only suitable when strict criteria exclude invasion and glandular disease.

Test of cure is HPV based. Six months after treatment for CIN1, CIN2 or CIN3, any hrHPV-positive result leads back to colposcopy with reflex cytology used to inform the examination. An hrHPV-negative result leads to recall in 3 years irrespective of age; if that test is also negative, the person can move to the routine 5-year interval. This early 3-year step prevents the 2025 interval extension from being applied too soon after treatment.

Glandular disease needs a separate pathway because lesions may extend into the canal and be multifocal. CGIN or SMILE is investigated with an excisional specimen including the endocervical canal rather than a punch biopsy alone. After complete excision, test of cure is performed at 6 months and, if hrHPV negative, again 12 months later, which is 18 months after treatment. Two negative tests permit 3-year recall; positivity at either point returns to colposcopy. Incomplete excision or discordant results require MDT planning.

Pregnancy changes treatment timing but not the need to exclude invasion. An abnormal screening referral should still attend expert colposcopy, usually in the late first or early second trimester. The programme does not recommend endocervical curettage as a substitute for adequate assessment. Biopsy and CIN treatment are usually deferred when invasion is not suspected, but a concerning lesion requires adequate biopsy with haemorrhage-capable facilities and urgent specialist management. Plan later-pregnancy surveillance or reassessment about 3 months postpartum explicitly.

Key points

  • In primary HPV screening, abnormal reflex cytology with hrHPV positivity leads to colposcopy; hrHPV positivity with negative cytology enters timed repeat testing.
  • After hrHPV-positive, cytology-negative screening, repeat HPV testing at 12 months; if still positive with negative cytology, repeat after another 12 months.
  • At 24 months, a third consecutive hrHPV-positive result requires colposcopy regardless of the cytology result; persistence, not one isolated HPV result, drives that referral.
  • If HPV is unavailable or cytology inadequate, repeat no sooner than 3 months; refer after the second consecutive unavailable or inadequate result.
  • Colposcopy examines the transformation zone under magnification after acetic acid, documents adequacy and lesion extent, and directs biopsy when histology is needed.
  • CIN1 often regresses and can be observed within the programme pathway; CIN3 is treated, while selected CIN2 decisions balance cancer prevention against reproductive consequences under specialist care.
  • After treatment for CIN1, CIN2 or CIN3, take the HPV test of cure at 6 months: hrHPV positivity returns to colposcopy, whereas hrHPV negativity leads to a 3-year recall before routine recall can resume.
  • Completely excised CGIN or SMILE has a distinct two-step test-of-cure schedule at 6 and 18 months before 3-year recall; do not
  • High-grade cytology with no matching colposcopic or histological explanation requires multidisciplinary reconciliation rather than discharge on a single reassuring view.
  • Pregnancy with suspected invasion requires expert colposcopy and oncology input; routine treatment should not be performed merely because HPV or CIN is present.
  • 05
    Post-treatment HPV test of cure
    Why
    Identify residual or recurrent HPV-associated disease after excision of CIN or glandular precancer.
    Interpretation and limitations
    For treated CIN, test at 6 months: any hrHPV positivity returns to colposcopy and negativity leads to 3-year recall; CGIN requires the additional 18-month test when the first is negative.
  • 2Take directed biopsy when histology is required and use diagnostic excision for indications such as unresolved high-grade or glandular disease, not simply because HPV is present.
  • 3Observe appropriate CIN1 and selected CIN2 within programme safeguards, treat CIN3 and suitable CIN2, and discuss every glandular or discordant case through the correct specialist pathway.
    • 03After treatmentComplete test of cure and failsafeCIN1, CIN2, CIN3, CGIN or SMILE has been treated and invasive cancer has not been diagnosed.+
    1. 1EscalationArrange the first clinician-taken hrHPV test of cure at 6 months and provide urgent advice for heavy bleeding, fever, escalating pain or offensive discharge after the procedure.
    2. 2After treated CIN, refer any hrHPV-positive result to colposcopy and set an hrHPV-negative result to 3-year recall before routine recall can resume.
    3. 3After completely excised CGIN or SMILE, repeat a negative 6-month test at 18 months, return two negative results to 3-year recall and send any positive result back to colposcopy.
    Clinical state
    JurisdictionUnited Kingdom
    apply the simpler CIN pathway.